Our study highlighted an elevated level of TILs and TAMs in GBM IDH-wt microenvironment; despite the fact that, to date, no immunotherapy has been granted regulatory approval, this observation highlights the importance of developing research into innovative immunotherapeutic approaches in the future [106]. The gene discussed is IDH1; the disease is glioblastoma.